Skip to main content
Top
Published in: Rheumatology International 3/2012

01-03-2012 | Original Article

Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity

Authors: Eiichi Tanaka, Ajitha Mannalithara, Eisuke Inoue, Noriko Iikuni, Atsuo Taniguchi, Shigeki Momohara, Gurkirpal Singh, Hisashi Yamanaka

Published in: Rheumatology International | Issue 3/2012

Login to get access

Abstract

We investigated the effect of long-term corticosteroid usage in suppressing the progression of functional disability in patients with early rheumatoid arthritis (RA). We studied 3,982 RA patients, who had continuous enrollment for at least 3 years, among 9,132 RA patients enrolled in an observational cohort study, IORRA, in Tokyo, Japan, from 2000 to 2007. The DAS28 and Japanese version of Health Assessment Questionnaire (J-HAQ) scores were collected at 6-month intervals (each phase). Among these patients, those with DAS28 values under 3.2 in all phases and RA disease duration under 2 years at study entry were selected as “early RA patients with well-controlled disease”. These patients were further classified into 3 groups based on average months of steroid usage per year: Non-users, Medium-users, and Frequent-users. Multiple linear regression analysis was used to study the relationship between steroid usage and the final J-HAQ scores. Among the 3,982 patients, 109 had DAS28 values under 3.2 in all the phases and were selected as study cohort. The average Final J-HAQ in Non-user (N = 64), in Medium-user (N = 25), in Frequent-user group (N = 20) was 0.04, 0.06, and 0.33, respectively. Multiple linear regression analysis after adjusting for all potential covariates confirmed that frequent steroid usage was the most significant factor associated with higher final J-HAQ scores (P < 0.05). Frequent steroid usage was associated with significantly higher final J-HAQ scores in early RA patients, even though their disease was managed efficiently by maintaining the DAS28 values under 3.2 over a long-term period.
Literature
1.
go back to reference Weaver AL (2004) The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 43(suppl 3): iii17–iii23 Weaver AL (2004) The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 43(suppl 3): iii17–iii23
2.
go back to reference Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW et al. (2005) Updated consensus statement on biological agents, specifically tumor necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 64(suppl 4): iv2–iv14 Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW et al. (2005) Updated consensus statement on biological agents, specifically tumor necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 64(suppl 4): iv2–iv14
3.
go back to reference Albers JM, Paimela L, Kurki P, Eberhardt KB, Emery P, van ‘t Hof MA et al (2001) Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis 60:453–458PubMedCrossRef Albers JM, Paimela L, Kurki P, Eberhardt KB, Emery P, van ‘t Hof MA et al (2001) Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis 60:453–458PubMedCrossRef
4.
go back to reference van Aken J, Lard LR, le Cessie S, Hazes JM, Breedveld FC, Huizinga TW (2004) Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 63:274–279PubMedCrossRef van Aken J, Lard LR, le Cessie S, Hazes JM, Breedveld FC, Huizinga TW (2004) Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 63:274–279PubMedCrossRef
5.
go back to reference Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS (2004) Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 43:906–914CrossRef Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS (2004) Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 43:906–914CrossRef
6.
go back to reference Pincus T, Marcum SB, Callahan LF (1992) Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 19:1885–1894PubMed Pincus T, Marcum SB, Callahan LF (1992) Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 19:1885–1894PubMed
7.
go back to reference Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 46:3136–3142PubMedCrossRef Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 46:3136–3142PubMedCrossRef
8.
go back to reference Moreland LW, O’Dell JR (2002) Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum 46:2553–2563PubMedCrossRef Moreland LW, O’Dell JR (2002) Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum 46:2553–2563PubMedCrossRef
9.
go back to reference Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259–266PubMedCrossRef Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A et al (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259–266PubMedCrossRef
10.
go back to reference Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G et al (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The methotrexate-cyclosporine combination study group. N Engl J Med 333:137–141PubMedCrossRef Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G et al (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The methotrexate-cyclosporine combination study group. N Engl J Med 333:137–141PubMedCrossRef
11.
go back to reference O’Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ et al (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334:1287–1291PubMedCrossRef O’Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ et al (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334:1287–1291PubMedCrossRef
12.
go back to reference Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563PubMedCrossRef Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563PubMedCrossRef
13.
go back to reference Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRef Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRef
14.
go back to reference Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343:1594–1602PubMedCrossRef Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343:1594–1602PubMedCrossRef
15.
go back to reference Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614–624PubMedCrossRef Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW et al (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614–624PubMedCrossRef
16.
go back to reference Kalla AA, Tikly M (2003) Rheumatoid arthritis in the developing world. Best Pract Res Clin Rheumatol 17:863–875PubMedCrossRef Kalla AA, Tikly M (2003) Rheumatoid arthritis in the developing world. Best Pract Res Clin Rheumatol 17:863–875PubMedCrossRef
17.
go back to reference Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group. N Engl J Med 333:142–146PubMedCrossRef Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group. N Engl J Med 333:142–146PubMedCrossRef
18.
go back to reference Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318PubMedCrossRef Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318PubMedCrossRef
19.
go back to reference van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1–12PubMed van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1–12PubMed
20.
go back to reference Hickling P, Jacoby RK, Kirwan JR (1998) Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and rheumatism council low dose glucocorticoid study group. Br J Rheumatol 37:930–936PubMedCrossRef Hickling P, Jacoby RK, Kirwan JR (1998) Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and rheumatism council low dose glucocorticoid study group. Br J Rheumatol 37:930–936PubMedCrossRef
21.
go back to reference Wassenberg S, Rau R, Steinfeld P, Zeidler H (2005) Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52:3371–3380PubMedCrossRef Wassenberg S, Rau R, Steinfeld P, Zeidler H (2005) Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52:3371–3380PubMedCrossRef
22.
go back to reference Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I (2005) Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52:3360–3370PubMedCrossRef Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I (2005) Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52:3360–3370PubMedCrossRef
23.
go back to reference Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381–3390PubMedCrossRef Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381–3390PubMedCrossRef
24.
go back to reference Kirwan JR, Bijlsma JWJ, Boers M, Shea BJ (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Rev 1:CD006356 Kirwan JR, Bijlsma JWJ, Boers M, Shea BJ (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Rev 1:CD006356
25.
go back to reference Criswell LA, Saag KG, Sems KM, Robinson V, Shea B, Wells G, Suarez-Almazor ME (1998) Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Rev 3:CD001158 Criswell LA, Saag KG, Sems KM, Robinson V, Shea B, Wells G, Suarez-Almazor ME (1998) Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Rev 3:CD001158
26.
go back to reference Gøtzsche PC, Johansen HK (2005) Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Rev 1:CD000189 Gøtzsche PC, Johansen HK (2005) Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Rev 1:CD000189
27.
go back to reference Saag KG, Criswell LA, Sems KM, Nettleman MD, Kolluri S (1996) Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum 39:1818–1825PubMedCrossRef Saag KG, Criswell LA, Sems KM, Nettleman MD, Kolluri S (1996) Low-dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum 39:1818–1825PubMedCrossRef
28.
go back to reference Gotzsche PC, Johansen HK (1998) Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 316:811–818PubMedCrossRef Gotzsche PC, Johansen HK (1998) Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 316:811–818PubMedCrossRef
29.
go back to reference Paulus HE, Di Primeo D, Sanda M, Lynch JM, Schwartz BA, Sharp JT et al (2000) Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. J Rheumatol 27:1632–1637PubMed Paulus HE, Di Primeo D, Sanda M, Lynch JM, Schwartz BA, Sharp JT et al (2000) Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. J Rheumatol 27:1632–1637PubMed
30.
go back to reference Hansen M, Podenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E et al (1999) A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis 58:713–718PubMedCrossRef Hansen M, Podenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E et al (1999) A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis 58:713–718PubMedCrossRef
31.
go back to reference Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J et al (2004) Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 63:797–803PubMedCrossRef Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J et al (2004) Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 63:797–803PubMedCrossRef
32.
go back to reference Iikuni N, Inoue E, Tanaka E, Hara M, Tomatsu T, Kamatani N et al (2008) Low disease activity state with corticosteroid may not represent ‘true’ low disease activity state in patients with rheumatoid arthritis. Rheumatology (Oxford) 47:519–521CrossRef Iikuni N, Inoue E, Tanaka E, Hara M, Tomatsu T, Kamatani N et al (2008) Low disease activity state with corticosteroid may not represent ‘true’ low disease activity state in patients with rheumatoid arthritis. Rheumatology (Oxford) 47:519–521CrossRef
33.
go back to reference Yamanaka H, Tohma S (2006) Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol 16:75–76PubMedCrossRef Yamanaka H, Tohma S (2006) Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol 16:75–76PubMedCrossRef
34.
go back to reference Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A et al (2003) Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum 49:784–788PubMedCrossRef Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A et al (2003) Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum 49:784–788PubMedCrossRef
35.
go back to reference Tanaka E, Saito A, Kamitsuji S, Yamada T, Nakajima A, Taniguchi A et al (2005) Impact of shoulder, elbow, and knee joint involvement on assessment of rheumatoid arthritis using the American College of rheumatology core data set. Arthritis Rheum 53:864–871PubMedCrossRef Tanaka E, Saito A, Kamitsuji S, Yamada T, Nakajima A, Taniguchi A et al (2005) Impact of shoulder, elbow, and knee joint involvement on assessment of rheumatoid arthritis using the American College of rheumatology core data set. Arthritis Rheum 53:864–871PubMedCrossRef
36.
go back to reference Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T et al (2007) Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. J Rheumatol 34:303–310PubMed Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T et al (2007) Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. J Rheumatol 34:303–310PubMed
37.
go back to reference Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A et al (2007) Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 17:283–289PubMedCrossRef Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A et al (2007) Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 17:283–289PubMedCrossRef
38.
go back to reference Nakajima A, Kamitsuji S, Saito A, Tanaka E, Nishimura K, Horikawa N et al (2006) Disability and patient’s appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. Mod Rheumatol 16:151–157PubMedCrossRef Nakajima A, Kamitsuji S, Saito A, Tanaka E, Nishimura K, Horikawa N et al (2006) Disability and patient’s appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. Mod Rheumatol 16:151–157PubMedCrossRef
39.
go back to reference Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T et al (2006) Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65:1661–1663PubMedCrossRef Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T et al (2006) Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65:1661–1663PubMedCrossRef
40.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1998) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1998) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRef
41.
go back to reference van der Heijde DM, van ‘t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA et al. (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49:916–920 van der Heijde DM, van ‘t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA et al. (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49:916–920
42.
go back to reference Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48 Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48
43.
go back to reference Iikuni N, Nakajima A, Inoue E, Tanaka E, Okamoto H, Hara M et al (2007) What’s in season for rheumatoid arthritis patients? Seasonal fluctuations in disease activity. Rheumatology (Oxford) 46:846–848CrossRef Iikuni N, Nakajima A, Inoue E, Tanaka E, Okamoto H, Hara M et al (2007) What’s in season for rheumatoid arthritis patients? Seasonal fluctuations in disease activity. Rheumatology (Oxford) 46:846–848CrossRef
44.
go back to reference Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM (1999) Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 42:1854–1860PubMedCrossRef Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM (1999) Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 42:1854–1860PubMedCrossRef
45.
go back to reference Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL (2001) The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44:2009–2017PubMedCrossRef Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL (2001) The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 44:2009–2017PubMedCrossRef
46.
go back to reference Guillemin F, Briancon S, Pourel J (1992) Functional disability in rheumatoid arthritis: two different models in early and established disease. J Rheumatol 19:366–369PubMed Guillemin F, Briancon S, Pourel J (1992) Functional disability in rheumatoid arthritis: two different models in early and established disease. J Rheumatol 19:366–369PubMed
47.
go back to reference Combe B, Cantagrel A, Goupille P, Bozonnat MC, Sibilia J, Eliaou JF et al (2003) Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. J Rheumatol 30:2344–2349PubMed Combe B, Cantagrel A, Goupille P, Bozonnat MC, Sibilia J, Eliaou JF et al (2003) Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis. J Rheumatol 30:2344–2349PubMed
48.
go back to reference Jansen LM, van Schaardenburg D, van Der Horst-Bruinsma IE, Bezemer PD, Dijkmans BA (2000) Predictors of functional status in patients with early rheumatoid arthritis. Ann Rheum Dis 59:223–226PubMedCrossRef Jansen LM, van Schaardenburg D, van Der Horst-Bruinsma IE, Bezemer PD, Dijkmans BA (2000) Predictors of functional status in patients with early rheumatoid arthritis. Ann Rheum Dis 59:223–226PubMedCrossRef
49.
go back to reference Guillemin F, Suurmeijer T, Krol B, Bombardier C, Briancon S, Doeglas D et al (1994) Functional disability in early rheumatoid arthritis: description and risk factors. J Rheumatol 21:1051–1055PubMed Guillemin F, Suurmeijer T, Krol B, Bombardier C, Briancon S, Doeglas D et al (1994) Functional disability in early rheumatoid arthritis: description and risk factors. J Rheumatol 21:1051–1055PubMed
50.
go back to reference van der Heijde DM, van’t Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51:177–181 van der Heijde DM, van’t Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51:177–181
51.
go back to reference Smedstad LM, Kvien TK, Moum T, Vaglum P (1995) Life events, psychosocial factors, and demographic variables in early rheumatoid arthritis: relations to one-year changes in functional disability. J Rheumatol 22:2218–2225PubMed Smedstad LM, Kvien TK, Moum T, Vaglum P (1995) Life events, psychosocial factors, and demographic variables in early rheumatoid arthritis: relations to one-year changes in functional disability. J Rheumatol 22:2218–2225PubMed
52.
go back to reference Uhlig T, Smedstad LM, Vaglum P, Moum T, Gerard N, Kvien TK (2000) The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up. Rheumatology (Oxford) 39:732–741CrossRef Uhlig T, Smedstad LM, Vaglum P, Moum T, Gerard N, Kvien TK (2000) The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up. Rheumatology (Oxford) 39:732–741CrossRef
53.
go back to reference Townsend HB, Saag KG (2004) Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks. Clin Exp Rheumatol 22:S77–S82PubMed Townsend HB, Saag KG (2004) Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks. Clin Exp Rheumatol 22:S77–S82PubMed
54.
go back to reference Bijlsma JW, Hoes JN, Van Everdingen AA, Verstappen SM, Jacobs JW (2006) Are glucocorticoids DMARDs? Ann N Y Acad Sci 1069:268–274PubMedCrossRef Bijlsma JW, Hoes JN, Van Everdingen AA, Verstappen SM, Jacobs JW (2006) Are glucocorticoids DMARDs? Ann N Y Acad Sci 1069:268–274PubMedCrossRef
55.
go back to reference Bijlsma JW, Van Everdingen AA, Huisman M, De Nijs RN, Jacobs JW (2002) Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann N Y Acad Sci 966:82–90PubMedCrossRef Bijlsma JW, Van Everdingen AA, Huisman M, De Nijs RN, Jacobs JW (2002) Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann N Y Acad Sci 966:82–90PubMedCrossRef
56.
go back to reference Guidelines for the management of rheumatoid arthritis (2002) 2002 Update. American College of rheumatology subcommittee on rheumatoid arthritis guidelines. Arthritis Rheum 46:328–346CrossRef Guidelines for the management of rheumatoid arthritis (2002) 2002 Update. American College of rheumatology subcommittee on rheumatoid arthritis guidelines. Arthritis Rheum 46:328–346CrossRef
57.
go back to reference van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845–1850PubMedCrossRef van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845–1850PubMedCrossRef
58.
go back to reference Makinen H, Kautiainen H, Hannonen P, Mottonen T, Leirisalo-Repo M, Laasonen L et al (2007) Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 34:316–321PubMed Makinen H, Kautiainen H, Hannonen P, Mottonen T, Leirisalo-Repo M, Laasonen L et al (2007) Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 34:316–321PubMed
59.
go back to reference Pincus T, Yazici Y, Bergman M, Swearingen C, Harrington T (2006) A proposed approach to recognise “near-remission” quantitatively without formal joint counts or laboratory tests: a patient self-report questionnaire routine assessment of patient index data (RAPID) score as a guide to a “continuous quality improvement” s. Clin Exp Rheumatol 24:S060–S073 Pincus T, Yazici Y, Bergman M, Swearingen C, Harrington T (2006) A proposed approach to recognise “near-remission” quantitatively without formal joint counts or laboratory tests: a patient self-report questionnaire routine assessment of patient index data (RAPID) score as a guide to a “continuous quality improvement” s. Clin Exp Rheumatol 24:S060–S073
60.
go back to reference Fransen J, Moens HB, Speyer I, van Riel PL (2005) Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 64:1294–1298PubMedCrossRef Fransen J, Moens HB, Speyer I, van Riel PL (2005) Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 64:1294–1298PubMedCrossRef
61.
go back to reference Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V (2004) Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum 50:364–371PubMedCrossRef Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V (2004) Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum 50:364–371PubMedCrossRef
62.
go back to reference Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43:1252–1255CrossRef Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43:1252–1255CrossRef
63.
go back to reference van Riel PL, van Gestel AM (2000) Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 59(suppl 1):i28–i31 van Riel PL, van Gestel AM (2000) Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 59(suppl 1):i28–i31
64.
go back to reference Sesin CA, Bingham CO (2005) Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 35:185–196PubMedCrossRef Sesin CA, Bingham CO (2005) Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 35:185–196PubMedCrossRef
65.
go back to reference Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N et al (2008) Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis 67:1153–1158PubMedCrossRef Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N et al (2008) Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis 67:1153–1158PubMedCrossRef
66.
go back to reference Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1995) Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 22:1055–1059PubMed Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1995) Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 22:1055–1059PubMed
67.
go back to reference McDougall R, Sibley J, Haga M, Russell A (1994) Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 21:1207–1213PubMed McDougall R, Sibley J, Haga M, Russell A (1994) Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 21:1207–1213PubMed
68.
go back to reference Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115–123PubMedCrossRef Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96:115–123PubMedCrossRef
Metadata
Title
Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity
Authors
Eiichi Tanaka
Ajitha Mannalithara
Eisuke Inoue
Noriko Iikuni
Atsuo Taniguchi
Shigeki Momohara
Gurkirpal Singh
Hisashi Yamanaka
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 3/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1638-4

Other articles of this Issue 3/2012

Rheumatology International 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.